Archives

MesoPher is a personalised DC therapy consisting of autologous DCs loaded with PheraLys, Amphera’s proprietary allogeneic lysate of mesothelioma cell lines. PheraLys, first developed for mesothelioma, contains a broad repertoire of tumour-associated antigens, many of which are also present in pancreatic cancer and other cancers.

Preclinical results showed that DCs loaded with mesothelioma cell lysate can induce T-cell immunity and reduce tumour growth in mice with pancreatic cancer. In mice with established pancreatic cancer (mimicking the situation of non-resected pancreatic cancer patients) synergistic anti-tumour effects were achieved when DC vaccination was combined with a CD40-agonist. The DC/αCD40 combination therapy was

At the (virtual) 15th Meeting of the International Mesothelioma Interest Group (iMig2021), Bob Belderbos of Erasmus MC, The Netherlands presented a poster on the DENIM study. His contribution (P038) can be found here on p174.

Dr Bob Belderbos presented the DENIM study as clinical trial in progress at the virtual WCLC2020. The title of his presentation was: P24.03 – A Multicenter Randomized Phase III Trial of Dendritic Cell Maintenance Therapy After Chemotherapy in Mesothelioma; Denim Trial. The abstract can be found here.

An article on the DENIM study was recently published in Translational Lung Cancer Research: http://tlcr.amegroups.com/article/view/29434

Proprietary immuno-oncology approach harnesses autologous dendritic cell therapy

`s-Hertogenbosch,
The Netherlands, 21 May 2019. Amphera B.V., an advanced-clinical-stage
biotechnology company developing dendritic cell therapies to treat cancer,
announces that it has recruited the first patients to a phase II study of
MesoPher to treat pancreatic cancer.

REACtiVe
(Rotterdam pancrEAtic cancer Vaccination trial) is an open-label phase II study
in 10 adult patients with surgically resected pancreatic cancer who have
received adjuvant standard of care treatment.

MesoPher, a personalised immuno-oncology cell therapy, is comprised
of autologous dendritic cells loaded with PheraLys, Amphera’s proprietary
allogeneic lysate of mesothelioma cell lines. PheraLys, first developed for
mesothelioma, contains a broad-spectrum of tumour-associated antigens,
many of

Amphera is one of the ten winners of the Academic Startup Competition. This was announced by a professional jury in Amsterdam in the presence of State Secretary for Economic Affairs and Climate, Mona Keijzer.

As a result of the selection, Amphera will be able to pitch at the Global Entrepreneurship Summit (GES) and will be offered a trip to Silicon Valley by the Ministry of Economic Affairs and Climate Change. The GES will give Amphera the opportunity to learn how to scale up their innovation faster and take the step from startup to scale-up.

The 10 winners of the Academic Startup

New data suggests high level of disease control possible with combination of dendritic cell therapy and PD-1/PD-L1 checkpoint inhibitors

`s-Hertogenbosch, The Netherlands, 3 April 2019. Amphera B.V., an advanced-clinical-stage biotechnology company developing dendritic cell therapies to treat cancer, presented data from patients that received a combination of its dendritic cell therapy product MesoPher with marketed checkpoint inhibitors, to treat mesothelioma. The data was presented at the AACR Annual Meeting 2019 in Atlanta, Georgia.

Dendritic Cells (DCs) capture, process, and present antigens to the immune system. However, mesothelioma suppresses the differentiation, maturation and therefore immuno-stimulatory function of

Proprietary immuno-oncology approach harnesses
autologous dendritic cell therapy to treat an orphan-designated cancer

`s-Hertogenbosch,
The Netherlands, 18 March 2019.
Amphera B.V., an advanced-clinical-stage biotechnology company developing
dendritic cell therapies to treat cancer, announces that it has recruited the
first patients to its pivotal phase II/III study of MesoPher to treat pleural
mesothelioma, a rare cancer of the lining of the lungs.

DENIM (DENdritic cell Immunotherapy for Mesothelioma) is
an open-label, randomised, phase II/III study in 230 adults with pleural
mesothelioma, to assess the efficacy and anti-tumour activity of MesoPher as
maintenance treatment after chemotherapy. Patients in Arm A will receive 3
bi-weekly injections of MesoPher with best supportive care, plus

On March 15, 2018 prof Joachim Aerts MD of Erasmus MC received a “Parel” (Pearl) from ZonMW for his research on dendritic cell immunotherapy MesoPher for mesothelioma. ZonMW is the The Netherlands Organisation for Health Research and Development.

The Dutch patient association, Asbestslachtoffers Vereniging Nederland (AVN) and Amphera received an “Oorkonde” (certificate) for their contributions to this study.

Amphera truly appreciates the Oorkonde, as it is an acknowledgement of the productive collaboration between an academic hospital, a patient association and a small biotech company.

More information (in Dutch) can be found on: https://www.zonmw.nl/nl/actueel/nieuws/detail/item/zonmw-parel-voor-afweerreactie-tegen-asbestkanker